期刊
CURRENT MEDICINAL CHEMISTRY
卷 21, 期 35, 页码 4046-4058出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867321666140915141332
关键词
Atherosclerosis; cannabinoids; CB2; ischemia/reperfusion injury; ischemic stroke
资金
- European Commission [FP7-INNOVATION I HEALTH-F2-2013-602114]
- Swiss National Science Foundation [310030_152639/1, 310030_152912/1]
- Foundation Gustave and Simone Prevot
- Foundation Leenaards
- Swiss National Science Foundation (SNF) [310030_152912] Funding Source: Swiss National Science Foundation (SNF)
In the last decades, the cannabinoid system (comprising synthetic and endogenous cannabinoid agonists and antagonists, their receptors and degrading enzymes) has been shown to induce potent immunomodulatory activities in atherogenesis and acute ischemic complications. Different from the other cannabinoid receptors in which controversial results are reported, the selective activation of the cannabinoid receptor type 2 (CB2) has been shown to play anti-inflammatory and protective actions within atherosclerotic vessels and downstream ischemic peripheral organs. CB2 is a transmembrane receptor that triggers protective intracellular pathways in cardiac, immune and vascular cells in both human and animal models of atherosclerosis. Considering basic research data, medications activating CB2 function in the circulation or peripheral target organs might be a promising approach against atherogenesis. This review updates evidence from preclinical studies on different CB2-triggered pathways in atherosclerosis and acute ischemic events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据